Anticitrullinated protein/peptide antibodies in rheumatoid arthritis;Anticitrullinierte protein/peptid-antikörper bei rheumatoider arthritis

Deutsches Arzteblatt

Volumn 106, Issue 10, 2009, Pages 157-158

  Gross, Wolfgang L ^a   Moosig, Frank ^a   Lamprecht, Peter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPERINUCLEAR FACTOR; EPITOPE; ETANERCEPT; FILAGGRIN; HLA DR ANTIGEN; INFLIXIMAB; KERATIN ANTIBODY; METHOTREXATE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PEPTIDE ANTIBODY; PREDNISONE; SALAZOSULFAPYRIDINE; VIMENTIN;

ANTIBODY TITER; COMBINATION CHEMOTHERAPY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; EDITORIAL; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; JOINT FUNCTION; PATHOGENESIS; PROTEIN PROCESSING; REMISSION; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; SMOKING; TREATMENT OUTCOME; WORK CAPACITY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; HUMANS; PEPTIDES, CYCLIC; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 67049154313     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0157     Document Type: Editorial

References (12)

1. Farragher TM, Goodson NJ, Naseem H et al.: Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58: 359-369
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allart CF et al.: Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146: 406-415
3. Emery P, Breedveld FC, Hall S et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind parallel treatment trial. Lancet 2008; 372: 375-382
4. Egerer K, Feist E, Burmester GR: The serological diagnosis of rheumatoid arthritis - antibodies to citrullinated antigens. Dtsch Ärztebl Int 2009; 106(10): 159-163
5. Syversen SW, Gaarder PI, Goll GL et al.: High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008; 67: 212-217
6. Meyer O, Labarre C, Dougados M et al.: Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-126 (Pubitemid 36135386)
7. Wiik AS: The immune response to citrullinated proteins in patients with rheumatoid arthritis: genetic, clinical, technical, and epidemiological aspects. Clin Rev Allergy Immunol 2007; 32: 13-22.
8. van der Helm-van Mil AH, Huizinga TW: Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res Ther 2008; 10: 205.
9. Yamamoto K, Yamada R: Lessons from a genome wide association study in rheumatoid arthritis. New Engl J Med 2007; 357: 1250-1251 (Pubitemid 47443187)
10. Caspi D, Anouk M, Golan I et al.: Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. Arthritis Rheum 2006; 55: 53-56 (Pubitemid 43235127)
11. Bang H, Egerer K, Gauliard A et al.: Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56: 2503-2511 (Pubitemid 47237269)
12. Mathsson L, Mullazehi M, Wick MC et al.: Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared to antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008; 58: 36-45.